Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease

Larisa Broglie*, Alfred Rademaker, John Galvin, Ayita Ray, William T. Tse, Reggie Duerst, Jennifer Schneiderman, Morris Kletzel, Sonali Chaudhury

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Background: Acute graft versus host disease (aGVHD) affects approximately 30–60% of patients after allogeneic hematopoietic stem cell transplantation (HCT) and our ability to predict who develops this complication and their response to treatment is limited. Fecal calprotectin has recently gained popularity as an effective marker of GI inflammation in patients with Inflammatory Bowel Disease (IBD). Methods: Fecal calprotectin and albumin were evaluated as prognostic and predictive markers of aGVHD in 60 adult and pediatric HCT patients. Stool samples were sent for calprotectin quantification prior to starting conditioning, at day 14 post-HCT, at day 28 post-HCT, and at onset of aGVHD ± 2 days. Results: Fecal calprotectin did not differentiate patients with GI-GVHD and non-GI GVHD and did not vary based on severity. However, in patients with steroid-refractory GI aGVHD, significantly higher fecal calprotectin levels were noted. At onset of lower-GI symptoms, steroid refractory patients (n = 3) had a mean fecal calprotectin level of 449 ug/g (range 116–1111 ug/g) and a mean albumin of 1.93 g/dL (range 1.6–2.3 g/dL) compared with a mean fecal calprotectin of 24 ug/g (range 16–31 ug/g) and a mean albumin of 3.3 g/dL (range 2.3–3.9 g/dL) in steroid responsive patients (n = 9) (fecal calprotectin p = 0.032, albumin p = 0.027). Conclusion: Patients with steroid-refractory GI aGVHD had higher fecal calprotectin levels and lower albumin levels than patients with steroid-responsive disease. We recommend further studies to evaluate non-invasive tests with fecal calprotectin in combination with albumin in predicting steroid refractory disease at onset of symptoms to potentially identify patients that may benefit from upfront escalation in GVHD treatment.

Original languageEnglish (US)
Pages (from-to)169-174
Number of pages6
JournalHematology/ Oncology and Stem Cell Therapy
Volume11
Issue number3
DOIs
StatePublished - Sep 2018

Fingerprint

Leukocyte L1 Antigen Complex
Graft vs Host Disease
Serum Albumin
Albumins
Hematopoietic Stem Cell Transplantation
Steroids
Inflammatory Bowel Diseases

Keywords

  • Albumin
  • Calprotectin
  • GVHD

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{093b38f5cf62419f937451698a5174a1,
title = "Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease",
abstract = "Background: Acute graft versus host disease (aGVHD) affects approximately 30–60{\%} of patients after allogeneic hematopoietic stem cell transplantation (HCT) and our ability to predict who develops this complication and their response to treatment is limited. Fecal calprotectin has recently gained popularity as an effective marker of GI inflammation in patients with Inflammatory Bowel Disease (IBD). Methods: Fecal calprotectin and albumin were evaluated as prognostic and predictive markers of aGVHD in 60 adult and pediatric HCT patients. Stool samples were sent for calprotectin quantification prior to starting conditioning, at day 14 post-HCT, at day 28 post-HCT, and at onset of aGVHD ± 2 days. Results: Fecal calprotectin did not differentiate patients with GI-GVHD and non-GI GVHD and did not vary based on severity. However, in patients with steroid-refractory GI aGVHD, significantly higher fecal calprotectin levels were noted. At onset of lower-GI symptoms, steroid refractory patients (n = 3) had a mean fecal calprotectin level of 449 ug/g (range 116–1111 ug/g) and a mean albumin of 1.93 g/dL (range 1.6–2.3 g/dL) compared with a mean fecal calprotectin of 24 ug/g (range 16–31 ug/g) and a mean albumin of 3.3 g/dL (range 2.3–3.9 g/dL) in steroid responsive patients (n = 9) (fecal calprotectin p = 0.032, albumin p = 0.027). Conclusion: Patients with steroid-refractory GI aGVHD had higher fecal calprotectin levels and lower albumin levels than patients with steroid-responsive disease. We recommend further studies to evaluate non-invasive tests with fecal calprotectin in combination with albumin in predicting steroid refractory disease at onset of symptoms to potentially identify patients that may benefit from upfront escalation in GVHD treatment.",
keywords = "Albumin, Calprotectin, GVHD",
author = "Larisa Broglie and Alfred Rademaker and John Galvin and Ayita Ray and Tse, {William T.} and Reggie Duerst and Jennifer Schneiderman and Morris Kletzel and Sonali Chaudhury",
year = "2018",
month = "9",
doi = "10.1016/j.hemonc.2017.12.003",
language = "English (US)",
volume = "11",
pages = "169--174",
journal = "Hematology/ Oncology and Stem Cell Therapy",
issn = "1658-3876",
publisher = "King Faisal Specialist Hospital and Research Centre",
number = "3",

}

Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease. / Broglie, Larisa; Rademaker, Alfred; Galvin, John; Ray, Ayita; Tse, William T.; Duerst, Reggie; Schneiderman, Jennifer; Kletzel, Morris; Chaudhury, Sonali.

In: Hematology/ Oncology and Stem Cell Therapy, Vol. 11, No. 3, 09.2018, p. 169-174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease

AU - Broglie, Larisa

AU - Rademaker, Alfred

AU - Galvin, John

AU - Ray, Ayita

AU - Tse, William T.

AU - Duerst, Reggie

AU - Schneiderman, Jennifer

AU - Kletzel, Morris

AU - Chaudhury, Sonali

PY - 2018/9

Y1 - 2018/9

N2 - Background: Acute graft versus host disease (aGVHD) affects approximately 30–60% of patients after allogeneic hematopoietic stem cell transplantation (HCT) and our ability to predict who develops this complication and their response to treatment is limited. Fecal calprotectin has recently gained popularity as an effective marker of GI inflammation in patients with Inflammatory Bowel Disease (IBD). Methods: Fecal calprotectin and albumin were evaluated as prognostic and predictive markers of aGVHD in 60 adult and pediatric HCT patients. Stool samples were sent for calprotectin quantification prior to starting conditioning, at day 14 post-HCT, at day 28 post-HCT, and at onset of aGVHD ± 2 days. Results: Fecal calprotectin did not differentiate patients with GI-GVHD and non-GI GVHD and did not vary based on severity. However, in patients with steroid-refractory GI aGVHD, significantly higher fecal calprotectin levels were noted. At onset of lower-GI symptoms, steroid refractory patients (n = 3) had a mean fecal calprotectin level of 449 ug/g (range 116–1111 ug/g) and a mean albumin of 1.93 g/dL (range 1.6–2.3 g/dL) compared with a mean fecal calprotectin of 24 ug/g (range 16–31 ug/g) and a mean albumin of 3.3 g/dL (range 2.3–3.9 g/dL) in steroid responsive patients (n = 9) (fecal calprotectin p = 0.032, albumin p = 0.027). Conclusion: Patients with steroid-refractory GI aGVHD had higher fecal calprotectin levels and lower albumin levels than patients with steroid-responsive disease. We recommend further studies to evaluate non-invasive tests with fecal calprotectin in combination with albumin in predicting steroid refractory disease at onset of symptoms to potentially identify patients that may benefit from upfront escalation in GVHD treatment.

AB - Background: Acute graft versus host disease (aGVHD) affects approximately 30–60% of patients after allogeneic hematopoietic stem cell transplantation (HCT) and our ability to predict who develops this complication and their response to treatment is limited. Fecal calprotectin has recently gained popularity as an effective marker of GI inflammation in patients with Inflammatory Bowel Disease (IBD). Methods: Fecal calprotectin and albumin were evaluated as prognostic and predictive markers of aGVHD in 60 adult and pediatric HCT patients. Stool samples were sent for calprotectin quantification prior to starting conditioning, at day 14 post-HCT, at day 28 post-HCT, and at onset of aGVHD ± 2 days. Results: Fecal calprotectin did not differentiate patients with GI-GVHD and non-GI GVHD and did not vary based on severity. However, in patients with steroid-refractory GI aGVHD, significantly higher fecal calprotectin levels were noted. At onset of lower-GI symptoms, steroid refractory patients (n = 3) had a mean fecal calprotectin level of 449 ug/g (range 116–1111 ug/g) and a mean albumin of 1.93 g/dL (range 1.6–2.3 g/dL) compared with a mean fecal calprotectin of 24 ug/g (range 16–31 ug/g) and a mean albumin of 3.3 g/dL (range 2.3–3.9 g/dL) in steroid responsive patients (n = 9) (fecal calprotectin p = 0.032, albumin p = 0.027). Conclusion: Patients with steroid-refractory GI aGVHD had higher fecal calprotectin levels and lower albumin levels than patients with steroid-responsive disease. We recommend further studies to evaluate non-invasive tests with fecal calprotectin in combination with albumin in predicting steroid refractory disease at onset of symptoms to potentially identify patients that may benefit from upfront escalation in GVHD treatment.

KW - Albumin

KW - Calprotectin

KW - GVHD

UR - http://www.scopus.com/inward/record.url?scp=85041593251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041593251&partnerID=8YFLogxK

U2 - 10.1016/j.hemonc.2017.12.003

DO - 10.1016/j.hemonc.2017.12.003

M3 - Article

C2 - 29397331

AN - SCOPUS:85041593251

VL - 11

SP - 169

EP - 174

JO - Hematology/ Oncology and Stem Cell Therapy

JF - Hematology/ Oncology and Stem Cell Therapy

SN - 1658-3876

IS - 3

ER -